大分割与常规分割全乳照射的三年结局:一项随机非劣效性临床试验结果
该随机多中心非劣效试验纳入287例0-II期乳腺癌患者,比较常规分割全乳照射(50 Gy/25次+10-14 Gy/5-7次)与大分割全乳照射(42.56 Gy/16次+10-12.5 Gy/4-5次)。中位随访4.1年,大分割组3年不良美容结局绝对风险8.2% vs 常规分割组13.6%(非劣效P=.002),两组3年局部无复发生存率均为99%(P=.37)。
要点
- 大分割全乳照射3年不良美容结局非劣于常规分割,绝对风险降低5.4%(8.2% vs 13.6%)。
- 化疗亚组中大分割组不良美容结局较常规分割组高4.1%(90%置信上限15.0%)。
- 大乳房亚组中大分割组不良美容结局较常规分割组低18.6%(90%置信上限-8.0%)。
核心结论
- 全乳照射加瘤床补量后3年,大分割与常规分割结局相似;瘤床补量、化疗和较大乳房尺寸似乎不是大分割全乳照射的强烈禁忌证。
研究设计与样本
- 随机、多中心、非劣效性临床试验,2011年至2014年纳入287例0-II期乳腺癌女性,随机分配至常规分割全乳照射或大分割全乳照射,按化疗、切缘状态、美容结局和乳房大小分层。
- 常规分割全乳照射方案为50 Gy/25次+10至14 Gy/5至7次,大分割全乳照射方案为42.56 Gy/16次+10至12.5 Gy/4至5次,主要终点为放疗后3年不良美容结局比例(采用乳腺癌治疗结局量表评估),分析为意向性治疗。
主要发现
- 286例患者接受了方案规定的放疗剂量,30%接受了化疗,36.9%乳房较大,中位随访4.1年。
- 大分割组3年不良美容结局绝对风险为8.2%(n=8),常规分割组为13.6%(n=15),大分割组低5.4%(非劣效P=.002)。
- 化疗患者中大分割组不良美容结局较常规分割组高4.1%(90%置信上限15.0%);乳房较大患者中大分割组不良美容结局较常规分割组低18.6%(90%置信上限-8.0%)。
- 照片评估美容结局差或一般的比例在常规分割组为28.8%,大分割组为35.4%(P=.31)。
- 两组3年局部无复发生存率均为99%(P=.37)。
关键数值与推荐
- 大分割全乳照射非劣效于常规分割全乳照射的假设成立(非劣效P=.002)。
- 3年不良美容结局绝对风险:大分割组8.2%(n=8)vs 常规分割组13.6%(n=15)。
临床怎么用
- 瘤床补量、化疗和较大乳房尺寸似乎不是大分割全乳照射的强烈禁忌证。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The adoption of hypofractionated whole-breast irradiation (HF-WBI) remains low, in part because of concerns regarding its safety when used with a tumor bed boost or in patients who have received chemotherapy or have large breast size. To address this, we conducted a randomized, multicenter trial to compare conventionally fractionated whole-breast irradiation (CF-WBI; 50 Gy/25 fx + 10 to 14 Gy/5 to 7 fx) with HF-WBI (42.56 Gy/16 fx + 10 to 12.5 Gy/4 to 5 fx). PATIENTS AND METHODS: From 2011 to 2014, 287 women with stage 0 to II breast cancer were randomly assigned to CF-WBI or HF-WBI, stratified by chemotherapy, margin status, cosmesis, and breast size. The trial was designed to test the hypothesis that HF-WBI is not inferior to CF-WBI with regard to the proportion of patients with adverse cosmetic outcome 3 years after radiation, assessed using the Breast Cancer Treatment Outcomes Scale. Secondary outcomes included photographically assessed cosmesis scored by a three-physician panel and local recurrence-free survival. Analyses were intention to treat. RESULTS: A total of 286 patients received the protocol-specified radiation dose, 30% received chemotherapy, and 36.9% had large breast size. Baseline characteristics were well balanced. Median follow-up was 4.1 years. Three-year adverse cosmetic outcome was 5.4% lower with HF-WBI ( Pnoninferiority = .002; absolute risks were 8.2% [n = 8] with HF-WBI v 13.6% [n = 15] with CF-WBI). For those treated with chemotherapy, adverse cosmetic outcome was higher by 4.1% (90% upper confidence limit, 15.0%) with HF-WBI than with CF-WBI; for large breast size, adverse cosmetic outcome was 18.6% lower (90% upper confidence limit, -8.0%) with HF-WBI. Poor or fair photographically assessed cosmesis was noted in 28.8% of CF-WBI patients and 35.4% of HF-WBI patients ( P = .31). Three-year local recurrence-free survival was 99% with both HF-WBI and CF-WBI ( P = .37). CONCLUSION: Three years after WBI followed by a tumor bed boost, outcomes with hypofractionation and conventional fractionation are similar. Tumor bed boost, chemotherapy, and larger breast size do not seem to be strong contraindications to HF-WBI.
引用
- Shaitelman SF, Lei X, Thompson A, et al. Three-Year Outcomes With Hypofractionated Versus Conventionally Fractionated Whole-Breast Irradiation: Results of a Randomized, Noninferiority Clinical Trial. J Clin Oncol. 2018. PMID: 30379626. doi:10.1200/JCO.18.00317
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。